Spun out of work from Jan Kraus' lab at the University of Colorado in 2013, Orphan Technologies Ltd. has moved its first drug into the clinic. The Lexington, Mass.-based company is part of the Neopharm group, of Petach Tikva, Israel, a private company owned by a single family.